Skip to main content
. Author manuscript; available in PMC: 2024 Dec 14.
Published in final edited form as: Cell. 2024 Oct 8;187(25):7196–7213.e26. doi: 10.1016/j.cell.2024.09.026

Figure 2. In vivo efficacy of VIR-7229.

Figure 2.

Virology and clinical endpoints on day 4 after SARS-CoV-2 XBB.1.5 or JN.1 infection of Syrian hamsters prophylactically administered with VIR-7229 (hamster Fc) or 1.5 mg/kg (mpk) isotype-matched control antibody. See also Data S3.

(A) Experiment outline.

(B) Infectious viral lung titers for XBB.1.5 infection. ND: not detected.

(C) Lung viral RNA load for XBB.1.5 infection. ND: not detected.

(D) Variation in body weight relative to day 0 for XBB.1.5 infection. No-infection control from the JN.1 experiment is provided for qualitative comparison.

(E) Cumulative clinical score for XBB.1.5 infection (0–4): ruffled fur, slow movements, apathy, absence of exploratory activity. No-infection control from the JN.1 experiment is provided for qualitative comparison.

(F) Infectious viral lung titers for JN.1 infection.

(G) Lung viral RNA load for JN.1 infection. ND: not detected.

(B-G) X-axis indicates dose of VIR-7229-hmFc or 1.5 mpk isotype control. Median ± interquartile range is shown; significance is based on ANOVA non-parametric Kruskal-Wallis test followed by Dunn’s multiple comparison test, *p<0.05, **p< 0.01, *** p < 0.001.